Full-Time
Certified Peer Specialist
Irts
Posted on 10/31/2025
BrightSpring Health Services
10,001+ employees
Home-based and community health services, pharmacy
Compensation Overview
$22/hr
Minneapolis, MN, USA
In Person
 Administrative & Executive Assistance (1) |
|---|
- Must be at least 21 years old.
- Have or had a primary diagnosis of mental illness.
- Be current or former consumer of mental health services.
- Demonstrate dedication to promoting recovery opportunities in lives of peers.
- Demonstrate ability to utilize own lived experience of recovery to inspire recovery in the lives of peers.
- Successfully complete the Minnesota Department of Human Services approved Certified Peer Specialist training and certification exam.
- Excellent communication skills both verbal and written.
- Excellent customer service skills.
- Ability to prioritize, meet deadlines and multitask.
- Experience with Microsoft Office (Word, Excel).
- Willingness to provide peer-recovery education.
- Assist peers with assessing their unique strengths and abilities.
- Help peers with identifying, developing and working towards recovery goals.
- Assist peers with developing self-advocacy skills.
- Help peers identify and access appropriate professional resources.
- Act as a community liaison.
- Provide education for team members regarding the recovery process.
- Assist in implementing and developing treatment goal plans.
- Sit in case management meetings.
- Provide care and resources for clients and staff on culture.
- Serves as a link to community resources, teaches and models client self-advocacy and acts as a community liaison/educator.
- Reports significant/major incidents or accidents.
- Medication administration.
- Adheres to data privacy practices/HIPAA.
- Writes progress notes and assists in summaries and discharges.
- Monitors and records, medication administration activities.
- Provides objective verbal and written critical incident analysis.
- Documents essential activities related to licensure, welfare and safety
BrightSpring Health Services provides home and community-based health care through two main operations: Pharmacy and Provider. In Pharmacy, it offers services for patients with complex and chronic conditions, including specialty, infusion, and community pharmacy solutions. In Provider, it delivers home health, behavioral health, hospice care, and services for intellectual and developmental disabilities. The company uses an integrated care model that connects pharmacy services with in-home care across its network to support patients, families, and managed care organizations. Revenue comes from reimbursed services paid by Medicare, Medicaid, and private insurers. Its goal is to coordinate ongoing, in-home and community-based care across a continuum—from pharmacy support to direct care—ensuring coordinated, patient-centered services for individuals with complex or chronic needs.
Company Size
10,001+
Company Stage
Post IPO Equity
Headquarters
Louisville, Kentucky
Founded
1974
Simplify's Take
What believers are saying
- Q1 2026 revenue grew 25.6% to $3.61 billion.[1]
- Specialty and infusion pharmacy revenue rose 35.5% year over year.[1]
- Management raised full-year 2026 guidance after beating EPS and revenue estimates.[1]
What critics are saying
- Heavy dependence on Medicare and Medicaid reimbursement exposes margins to rate pressure.[1][2]
- Integration of Amedisys and LHC branches can distract management and delay synergies.[1]
- Insider selling by Jon Rousseau and Lisa Nalley signals limited near-term confidence.[1]
What makes BrightSpring Health Services unique
- Integrated pharmacy and provider services target complex chronic-care populations.[1][2]
- National scale spans Pharmacy, Provider, and Managed Care services.[2][4]
- Technology-enabled care delivery supports outcomes across home and community settings.[1][2]
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at BrightSpring Health Services who can refer or advise you
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%BrightSpring Health Services announced the resignation of Robert Barnes as President of ResCare Community Living on 30 March 2026, stating it was not due to any disagreement over operations or policies. The company's shares rose 5.2% following upbeat analyst reports from its investor day. Management unveiled ambitious long-term organic EBITDA growth targets of 15% to 20% annually through 2028, alongside AI-driven efficiency plans for its home and community-based care platform. The narrative projects $16.8 billion in revenue and $361.8 million in earnings by 2028, requiring 10.1% yearly revenue growth. Investors remain focused on whether BrightSpring can balance acquisition-driven expansion and technology investment whilst managing its substantial debt load and regulatory exposure.
BrightSpring Health Services has seen its stock price surge 43.1% over the past six months to $42.32 per share, driven by strong quarterly results. The healthcare services company, founded in 1974, offers home health care, hospice, neuro-rehabilitation and pharmacy services. BrightSpring's revenue grew at an 18.3% compound annual growth rate over the past five years, outpacing the healthcare sector average. Analysts forecast 15% revenue growth over the next 12 months, though this represents a deceleration from its recent 20.9% annual rate. However, the company's five-year average return on invested capital of 4.9% falls below the typical cost of capital for healthcare firms, suggesting historically mediocre capital efficiency. The stock currently trades at 27.7× forward price-to-earnings ratio.
BrightSpring Health Services has raised questions about its valuation after trading at 24.5 times forward earnings following strong 2025 performance. The company reported fourth-quarter revenue of $3.55 billion, up 29.3% year-over-year, with adjusted EBITDA rising 40.7% to $184 million. For 2026, management guided revenue between $14.45 billion and $15 billion, representing 11.9% to 16.2% growth, whilst adjusted EBITDA is expected to grow faster at 23% to 28%, indicating margin expansion. However, the company faces approximately $600 million in revenue headwinds from Inflation Reduction Act impacts and brand-to-generic conversions. The valuation hinges on whether BrightSpring can deliver sequential profitability improvements throughout the year despite policy and product-mix pressures affecting headline revenue growth.
BrightSpring Health Services led senior health stocks in Q4 earnings, reporting revenues of $3.55 billion, up 16.3% year on year and beating analyst expectations by 5%. The company delivered strong full-year EBITDA guidance. In contrast, Chemed posted the weakest performance, with revenues of $639.3 million falling 3% short of expectations. The company missed both revenue and full-year EPS guidance estimates, sending shares down 19.2% to $377.07. The seven senior health, home health and hospice stocks tracked reported slower Q4 results overall, with revenues beating consensus estimates by just 1.1%. Share prices have declined an average of 9.6% since earnings releases. The sector faces headwinds from labour shortages and wage inflation whilst benefiting from an ageing population and growing preference for in-home care.
BrightSpring Health Services outlined its growth strategy at an investor day, highlighting a shift towards core home-and-community clinical services. The company's planned community-living divestiture will close soon to boost cash flow and support integrated care initiatives. BrightSpring reported significant deleveraging from approximately 4.5x post-IPO to 2.99x (2.6x pro forma), with leverage expected to fall below 2x in 2026. The company reiterated 2026 guidance of $14.45–$15.0 billion revenue and $760–$790 million adjusted EBITDA, whilst targeting 15–20% organic adjusted EBITDA compound annual growth for 2026–2028. The healthcare services provider has at least $2 billion available for acquisitions through 2028. Its operations include dispensing over 40 million prescriptions annually through PharMerica, serving more than 4 million patients, with recent branch integrations expected to add approximately $30 million of EBITDA.